Navigating a paradigm shift: Bruton’s tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112265 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Asad Gul Rao. Beteiligte Einrichtung: DOW Medical College, Baba-e-urdu Road, Saddar, Karachi, Pakistan. Electronic address: asadgulrao123@gmail.com. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Multiple Sclerosis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DOW Medical College, Baba-e-urdu Road, Saddar, Karachi, Pakistan. Electronic address: asadgulrao123@gmail.com.
Zitieren
APA
Rao, A. G. (2024). Navigating a paradigm shift: Bruton’s tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112265
Vancouver
Rao AG. Navigating a paradigm shift: Bruton’s tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112265
BibTeX
@article{Rao2024,
author = {Rao, Asad Gul},
title = {Navigating a paradigm shift: Bruton’s tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112265}
}
EUVIMED